Increased Prevalence of Fractures in Congenital Adrenal Hyperplasia: A Swedish Population-based National Cohort Study
Open accessThe DOI matches its Crossref record; 51 of the 54 references it cites were found in a registry or an index.
Abstract
Context: Low bone mineral density has been reported in individuals with congenital adrenal hyperplasia (CAH), but the prevalence of fractures is unclear. Objective: To study the prevalence of fractures in CAH. Design, Setting, and Participants: Patients with CAH (n = 714, all 21-hydroxylase deficiency) were compared with controls matched for sex and year and place of birth (n = 71 400). Data were derived by linking National Population-Based Registers. Main Outcome Measures: Number and type of fractures. Results: Mean age was 29.8 ± 18.4 years. Individuals with CAH had more fractures compared to controls [23.5% vs 16.1%, odds ratio (OR) 1.61, 95% CI 1.35-1.91], and this was found in both sexes (females: 19.6% vs 13.3%, OR 1.57, 95% CI 1.23-2.02; males: 28.7% vs 19.6%, OR 1.65, 95% CI 1.29-2.12). Fractures were significantly increased in patients born before the introduction of neonatal screening but not in those born afterwards. Any major fracture associated with osteoporosis (spine, forearm, hip, or shoulder) was increased in all individuals with CAH (9.8% vs 7.5%, OR 1.34, 95% CI 1.05-1.72). The highest prevalence of fractures was seen in SV phenotype and I172N genotype while nonclassic phenotype and I2 splice genotype did not show increased prevalence. A transport accident as a car occupant and fall on the same level were more common in patients with CAH, both sexes, than in controls. Conclusions: Patients with CAH had an increased prevalence of both any fracture and fractures associated with osteoporosis (both sexes) but not for patients neonatally screened. We conclude that fracture risk assessment and glucocorticoid optimization should be performed regularly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A population-based Swedish study (n = 714 patients with CAH and 71,400 control individuals) found an increased risk of fragility fractures in patients with CAH91.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506
Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment
Chotiyarnwong, P., & McCloskey, E. V. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0341-0 · Cited by 489
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313
Frisén, L., Nordenström, A., Falhammar, H., Filipsson, H., Holmdahl, G., Janson, P. O., Thorén, M., Hagenfeldt, K., Möller, A., & Nordenskjöld, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0636 · Cited by 276
Self-citationFalhammar, H., Frisén, L., Hirschberg, A. L., Norrby, C., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2093 · Cited by 204
Self-citationIncreased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Falhammar, H., Frisén, L., Norrby, C., Hirschberg, A. L., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2957 · Cited by 196
Self-citationGonadal and Adrenal Androgens Are Potent Regulators of Human Bone Cell Metabolism In Vitro
Kasperk, C. H., Wakley, G. K., Hierl, T., & Ziegler, R. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.3.464 · Cited by 196
Cited by
Congenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
Self-citationSecondary Osteoporosis and Metabolic Bone Diseases
Sobh, M., Abdalbary, M., Elnagar, S., Nagy, E., Elshabrawy, N. A., Abdelsalam, M., Asadipooya, K., & El-Husseini, A. A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092382 · Cited by 191
Management challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
Auchus, R. J., Hamidi, O., Pivonello, R., Bancos, I., Russo, G., Witchel, S. F., Isidori, A. M., Rodien, P., Srirangalingam, U., Kiefer, F. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404656 · Cited by 79
Self-citationLong-Term Outcomes of Congenital Adrenal Hyperplasia
Nordenström, A., Lajić, S., & Falhammar, H. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1528 · Cited by 49
“Recent epidemiological studies on the presence of fractures in patients with CAH have been reported [33,58].”
Self-citationChallenges in treatment of patients with non-classic congenital adrenal hyperplasia
Adriaansen, B. P. H., Schröder, M. A. M., Span, P. N., Sweep, F. C. G. J., van Herwaarden, A. E., & der Grinten, H. L. C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1064024 · Cited by 51
Sarafoglou, K., Merke, D. P., Reisch, N., der Grinten, H. L. C., Falhammar, H., & Auchus, R. J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad134 · Cited by 35
Self-citationLong‐term health consequences of congenital adrenal hyperplasia
Pofi, R., Ji, X., Krone, N. P., & Tomlinson, J. (2023) · Clinical Endocrinology · doi:10.1111/cen.14967 · Cited by 30
“153 It remains controversial as to whether BMD differs between SW and SV ‐ CAH.”
Cardiometabolic Aspects of Congenital Adrenal Hyperplasia
Krysiak, R. G., der Grinten, H. L. C., Reisch, N., Touraine, P. A., & Falhammar, H. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae026 · Cited by 26
Self-citationSahlander, F., Patrova, J., Mannheimer, B., Lindh, J. D., & Falhammar, H. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01933-0 · Cited by 24
Self-citationder Grinten, H. L. C., Adriaansen, B. P. H., & Falhammar, H. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae718 · Cited by 19
Self-citationThe epidemiology of disorders of sex development
Berglund, A., Chang, S., Lind‐Holst, M., Stochholm, K., & Gravholt, C. H. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102002 · Cited by 23
Characteristics of In2G Variant in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Kocova, M., Concolino, P., & Falhammar, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.788812 · Cited by 15
Self-citationEngberg, H., Nordenström, A., & Hirschberg, A. L. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae696 · Cited by 16
Self-citationRighi, B., Ali, S., Bryce, J., Tomlinson, J., Bonfig, W., Baronio, F., Costa, E. C., Guaragna‐Filho, G., T'Sjoen, G. G., Cools, M., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03330-w · Cited by 15
Self-citationConcolino, P., & Falhammar, H. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf018 · Cited by 12
“…1; HSD17B2, hydroxysteroid 17-beta dehydrogenase 2; SRD5A2, steroid 5 alpha-reductase 2. androgens, supraphysiological glucocorticoid therapy is usually required, with increased risk of long-term complications such as cardiometabolic diseases as well as osteoporosis and fractures [18, 19].”
Self-citationLoli, P., Menotti, S., di Filippo, L., & Giustina, A. (2025) · Endocrine · doi:10.1007/s12020-025-04341-5 · Cited by 16
“…patients, self reporting of fractures, unknown circumstances of fractures and higher prevalence of car accident and fall on same level among patients) this study support the hypothesis that supraphysiological replacement dosing and low androgen concentrations cause increased risk of fractures [88].”
Lee, D. H., Kong, S. H., Jang, H. N., Ahn, C. H., Lim, S. G., Lee, Y. A., Kim, S. W., & Kim, J. H. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01090-0 · Cited by 11
Hasenmajer, V., Ferrari, D., Alcubierre, D. D., Sada, V., Puliani, G., Bonaventura, I., Minnetti, M., Tomaselli, A., Pofi, R., Sbardella, E., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad151 · Cited by 11
“Collectively, an increased risk of osteoporotic fractures has been described in AI [11-15], and recent reports have suggested that patients with PAI might exhibit an increased rate of hip [14] and vertebral fractures [13] despite normal bone density, suggesting the presence of skeletal fragility…”
BackgroundBancos, I., Kim, H., Cheng, H. K.-H., Rodríguez-Lee, M., Coope, H., Cicero, S., Goldsmith, H., Lin, V. H., & Jeha, G. S. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2450423 · Cited by 9
“Adults with CAH are at risk of low bone mineral density (BMD), osteoporosis, and fractures due to GCs, which can inhibit bone formation and increase bone resorption upon initial treatment but decrease osteoclast activity (resorption) over the long term [15,16,24,99–101].”
Auchus, R. J., Courtillot, C., Dobs, A. S., El‐Maouche, D., Falhammar, H., Lacroix, A., Farrar, M., O’Donoghue, C., Anatchkova, M., Cutts, K. N., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1005963 · Cited by 9
Self-citationWiromrat, P., Namphaisan, P., Wongsurawat, N., Panamonta, O., & Nasomyont, N. (2022) · Clinical Endocrinology · doi:10.1111/cen.14809 · Cited by 6
“increased prevalence of fractures in children and adults with 21OHD as compared to matched controls.(3) As such, GC‐induced bone fragility is one of the major concerns in the long‐term care of 21OHD.”
BackgroundFalhammar, H., Hirschberg, A. L., Nordenskjöld, A., Larsson, H., & Nordenström, A. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad624 · Cited by 5
Self-citationStergianos, S., Spelman, T. D., Eriksson, D., Öster, S., Björnsdóttir, S., Kämpe, O., Skov, J., & Bensing, S. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20085 · Cited by 5
“Congenital adrenal hyperplasia (CAH) has also been associated with reduced BMD [33] and increased fracture risk [34].”
Navardauskaitė, R., Vanckavičienė, A., & Verkauskienė, R. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1456679 · Cited by 6
Pathophysiology and evaluation of bone health in adrenal diseases
Uygur, M. M., di Filippo, L., Frara, S., Menotti, S., & Giustina, A. (2025) · Endocrine · doi:10.1007/s12020-025-04260-5 · Cited by 5
“Recent studies have shown increased fracture rates, including osteoporotic fractures, in both sexes, which were signi fi cantly lower in patients neonatally screened, suggesting contemporary management of CAH may have improved bone health outcomes [13].”
Chen, S., Wu, L., Ma, X., Guo, L., Zhang, J., Gao, H., & Zhang, T. (2024) · Medicine · doi:10.1097/md.0000000000040297 · Cited by 4
Exploration of the potential of genomic editing in the treatment of congenital adrenal hyperplasia
Graves, L. E., Christina, S., Mullany, K., Alexander, I. E., & Falhammar, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1719376 · Cited by 2
Self-citationHamidi, O., Auchus, R. J., Correa, R. R., Levine, A. C., Wierman, M. E., Hartzell, A. L., Lin, V. H., & Bancos, I. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag147 · Cited by 4
Nordenström, A., & Falhammar, H. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100616 · Cited by 2
Self-citationSpecialty grand challenge in adrenal endocrinology
Falhammar, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1237733 · Cited by 2
Self-citationPrednisolone impairs trabecular bone score changes in adolescents with 21-hydroxylase deficiency
Wiromrat, P., Raruenrom, Y., Namphaisan, P., Wongsurawat, N., Panamonta, O., & Pongchaiyakul, C. (2024) · Korean Journal of Pediatrics · doi:10.3345/cep.2024.01060 · Cited by 2
Hormone replacement in disorders of sex development, and long-term effects
Nordenström, A., Mangone, A., & Mantovani, G. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102022 · Cited by 3
Self-citationRyabets‐Lienhard, A., Nguyen, J. N., Pickering, T. A., Fraga, N. R., Deras, E. A., Geffner, M. E., & Kim, M. S. (2025) · Hormone Research in Paediatrics · doi:10.1159/000548651 · Cited by 1
Scandrett, K., Dinnes, J., Morrison, B., Coombe, A., Agarwal, R., Asare, I. A., Mead, P. A., Souza, A. D., Elliman, D. A. C., Lombardo, S., et al. (2025) · Health Technology Assessment · doi:10.3310/gjjd1717 · Cited by 1
Advances in pharmacological treatment for congenital adrenal hyperplasia
Graves, L. E., & Falhammar, H. (2026) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001583 · Cited by 2
Self-citationYu, K., & Bancos, I. (2026) · Pituitary · doi:10.1007/s11102-026-01652-2
Nokoff, N., Fechner, P. Y., Kim, M. S., Marshall, I. H., Merke, D. P., Sarafoglou, K., Hartzell, A. L., Lin, V. H., & Thornton, P. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag192
Obesity in Classic Congenital Adrenal Hyperplasia: Mechanisms, Complications and Management
Mu, J., Li, Y. J., Sun, M., Li, Y. J., Li, P., & Zou, H. (2026) · Clinical Endocrinology · doi:10.1111/cen.70155
“Glucocorticoid‐induced osteoporosis is a recognised long‐term complication of pharmacological treatment that requires monitoring [66, 67].”
Kim, H., Lin, V. H., Newfield, R. S., Dauber, A., Luo, M., Cicero, S., Li, M., Zhao, C., & Cheng, H. K.-H. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag112
“Additional studies have similarly documented persistent adrenal androgen excess and metabolic morbidity despite GC therapy [12, 18, 32, 33].”
Crinecerfont: emerging role in the management of congenital adrenal hyperplasia
Fedorova, O., & Falhammar, H. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2713482
“…effective in reducing androgen excess, this approach is associated with numerous adverse effects, including cardiometabolic complications, short stature, reduced bone mineral density and fractures, particularly when high doses are used chronically during periods of growth and development [10–14].”
Self-citationThe evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Metadata
- Authors
- Falhammar, H., Frisén, L., Hirschberg, A. L., Nordenskjöld, A., Almqvist, C., & Nordenström, A.
- Affiliations
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Falhammar, Henrik
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2021-10-03
- Volume
- 107
- Issue
- 2
- Pages
- e475-e486
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC8764334
- OpenAlex
- W3202654528
- Cited by
- 42
- References
- 54
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 6 · 2023: 7 · 2022: 10
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Magnus Bergvall Foundation
- Karolinska Institutet
- Stockholm County Council
- Swedish Research Council (2017-02051)
- Swedish Initiative for Research on Microdata in the Social and Medical Sciences (340-2013-5867)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, fracture prevalence, osteoporosis, osteopenia, newborn screening, glucocorticoid therapy, fracture risk assessment, transport accidents, falls
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Adult, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Registries, Steroid 21-Hydroxylase, Sweden, Bone Density, Prevalence, Neonatal Screening, Case-Control Studies, Fractures, Bone, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.